Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells
Introduction
Inherent and treatment-induced chemoresistance is a major cause of therapeutic failure in clinical oncology. Chemoresistance is complex and multifactorial, influenced by cellular and molecular pharmacologic mechanisms, altered enzymatic pathways and expression of certain oncogenes 1, 2, 3. Among the best characterized and most widespread chemoresistance mechanisms in tumor cells, including leukemias [4], is expression of the p-170 multidrug-resistance (MDR) glycoprotein 5, 6, a member of the family of ATP-binding cassette-containing membrane transporters. This drug-efflux pump can sequester [7]or remove drugs from the cell 4, 5, 6to an extent that renders available intracellular drug levels incapable of inducing apoptosis.
Substrates for the MDR P-glycoproteins (P-gps) are as structurally diverse as the agents that demonstrate susceptibility to MDR; the latter include Vinca alkaloids, anthracyclines and epipodophyllotoxins. These substrates are generally characterized only as sharing an amphipathic nature, critical to their molecular binding interaction with the P-gp membrane pump. Some investigators propose that this binding occurs at the cytoplasmic leaflet of the plasma membrane followed by a transmembrane `flipping' of the polar group of the substrate by the P-gp out to the exoplasmic face [8].
Recent studies have demonstrated that both human isoforms of the P-gp, the gene products of mdr-1 and mdr-3, are lipid translocases 8, 9, 10, 11, 12. MDR1 P-gp translocated a wide variety of sphingolipids (SLs) to both apical and basolateral membranes at temperatures ≥20°C; these SLs included the fluorophores N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl sphingosine-1-phosphocholine (C6-NBD-sphingomyelin; SM) and C6-NBD-glucosyl-ceramide, as well as short-chain glucosyl-ceramide analogues [12]. Incubation at 15°C blocked the vesicle-dependent transport of C6-NBD-SM from the lumen of the Golgi; export of C6-NBD-glucosyl-ceramide from the cytoplasmic face of the Golgi and endoplasmic reticulum still occurred at this temperature and only in the MDR1 expressing cells, indicating an essential role for the P-gp in this translocation. These SLs were synthesized by the cells from a C6-NBD-ceramide precursor [13].
These observations of the structural specificity of MDR1 P-gp for SLs raise provocative questions in light of the recently disclosed role of SLs as putative downstream mediators in differentiative, growth-inhibitory and apoptotic pathways induced in tumor cells (reviewed in [14]). The SL ceramide, derived either from catalytic cleavage of sphingomyelin (SM) or via de novo synthesis triggered by exposure to a number of upstream stimuli, including differentiating agents and chemotherapeutic drugs, induces classical patterns of apoptosis in human HL-60 and U937 leukemia cells [15]as well as many other tumor targets; the latter involved the use of exogenously administered cell-permeable ceramide analogues. Similarly, the non-acylated counterpart of ceramide, sphingosine (So), is elevated during phorboid-induced differentiation of HL-60 cells [16]and induces growth-arrest and apoptosis in tumor cells following exogenous administration [17]. Of therapeutic relevance are the observations that So formulations have shown antitumor and antimetastatic activity in pre-clinical tumor models, although their mechanism of action is not unequivocally defined 18, 19, 20, 21.
In light of the activity of MDR1 against SL substrates, we predicted that the P-gp drug-efflux pump would protect cells against apoptosis/cytotoxicity, not only by exporting the upstream, proximal inducer of apoptosis, the chemotherapeutic agent itself, but also by exporting SLs, the distal mediators essential to the apoptotic pathway. The current studies were designed to test the latter aspect of this hypothesis in vitro.
Section snippets
Cell lines
The murine P388 myeloid leukemia cell line and its MDR-expressing counterpart were obtained from Dr. Roman Perez-Soler, Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center. The MDR line was selected from the parental by growth in the presence of increasing concentrations of doxorubicin (Dox) and displayed a stable resistance phenotype in the absence of further selection pressure. These lines were maintained in DMEM/F-12 medium (GIBCO,
Comparison of susceptibility of parental and MDR P388 cells to Dox cytotoxicity
Both parental and MDR P388 cells were cultured for up to 48 h in the presence of Dox, using a dose range established by twofold titrations from 5 μg/ml to ~6 ng/ml. The results from the MTT assay (shown in Fig. 2(A)) indicated that the ED50 for the parental cells was between 2.4 and 4.9 ng/ml, whereas the ED50 for the MDR cells was in the 0.625–1.25 μg/ml range (Fig. 2(B)). Comparison of the survival of parental cells treated with 2.4 ng/ml (74.5±1.3% survival) or 4.9 ng/ml Dox (33.9±1.5%
Discussion and conclusion
Our results demonstrate that the SLs C6-Cer, So and Sa exert cytotoxic effects in murine P388 leukemia cells irrespective of the expression of MDR in these cell lines. In light of the reported activity of MDR1 as a lipid translocase of broad selectivity and of the effectiveness of lipids with a ceramide backbone as substrates for the P-gp pump in this context 8, 12, we did not anticipate this result. In contrast, MDR3 has not been reported to display drug-pumping activity [24]and has a lipid
Acknowledgements
We thank Kim D. Steck and Douglas A. Weidner for conducting the flow cytometric analyses. These analyses were conducted with support from the Automated Cytometry component of the Cancer Center Support Grant CA 16672. We thank Michael S. Worley of the Department of Scientific Publications for helpful editorial comments.
References (29)
- et al.
An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro
Biochim Biophys Acta
(1992) - et al.
Is the multidrug transporter a flippase?
Trends Biochem Sci
(1992) - et al.
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
Cell
(1993) - et al.
Phosphatidylcholine translocase: a physiological role for the mdr2 gene
Cell
(1994) - et al.
Maintenance and consequences of membrane phospholipid asymmetry
Chem Phys Lipids
(1994) - et al.
MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine
Cell
(1996) - et al.
Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C
J Biol Chem
(1995) - et al.
Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines
Leuk Res
(1995) - et al.
Tumor necrosis factor-α (TNF-α) signal transduction through ceramide
J Biol Chem
(1993) - et al.
Inhibition of sphingolipid biosynthesis by fumonisins
J Biol Chem
(1991)
Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals
Cell
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26)
Cancer Res
Combined modalities of resistance in etoposide-resistant human KB cell lines
Cancer Res
Drug resistance modulation in the laboratory and the clinic
Semin Oncol
Cited by (20)
Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells
2015, Toxicology LettersCitation Excerpt :Neoplastic cells are known to be particularly susceptible. For example, in murine cell lines, sphingosine, dihydrosphingosine, and C6-ceramide are cytotoxic for murine P388 leukemia cells (EC50, 2.5–5.0 μM) and murine multi-drug resistant P388 leukemia cells (EC50, 5.0–10.0 μM) (Klostergaard et al., 1998). Phytosphingosine and phytosphingosine derivatives are cytotoxic to murine melanoma B16 cells (10.0–50.0 μM; IC50, 15 μM) (Rives et al., 2011).
Therapeutic Potential of Targeting SK1 in Human Cancers
2013, Advances in Cancer ResearchCitation Excerpt :Interestingly, SK1-specific siRNA or pharmacological inhibitors were shown to induce cancer cell apoptosis independently of p53 mutation (Pchejetski et al., 2005) or Bcl-2 status (Leroux et al., 2007), which implies that SK1 inhibition can override these important pathways of tumor progression. DHS and DMS were first shown to potentiate apoptotic mechanisms and overcoming radio and chemoresistance in AML (Cuvillier & Levade, 2001; Jendiroba, Klostergaard, Keyhani, Pagliaro, & Freireich, 2002; Klostergaard, Auzenne, & Leroux, 1998) or solid tumors such as breast adenocarcinoma (Maurer, Melton, Billups, Cabot, & Reynolds, 2000; Sachs, Safa, Harrison, & Fine, 1995), prostate adenocarcinoma (Nava et al., 2000; Sachs et al., 1995), cervix carcinoma (Shirahama et al., 1997), gastric adenocarcinoma (Schwartz et al., 1995), neuroblastoma (Maurer et al., 2000), melanoma (Maurer et al., 2000), lung (Maurer et al., 2000), colon (Maurer et al., 2000), and pancreas (Maurer et al., 2000). A concept of SK1 acting as a “sensor” to anticancer therapies was, therefore, introduced, where SK1 inhibition was proposed to correlate to therapy efficiency (Pchejetski et al., 2005).
Transport of lipids by ABC proteins: Interactions and implications for cellular toxicity, viability and function
2009, Chemico-Biological InteractionsCitation Excerpt :MDR1 promotes sphingomyelin externalization, resulting in lower levels of sphingomyelin available for ceramide synthesis on the intracellular side of the plasma membrane [213]. In response to treatment with the MDR1 inhibitor, PSC833, inner plasma membrane sphingomyelin levels increase together with enhanced sphingomyelinase activity and ceramide synthesis [214], although there is concern over the interpretation of these studies since the effects of PSC833 may be MDR1-independent [206]. MDR1 is also expressed in the mitochondria of drug-resistant cells, where it may interfere with aspects of apoptosis in response to anticancer drugs via blocking the release of cytochrome c into the cytosol [5].
Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells
2004, Experimental Cell ResearchEnzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer
2003, Pharmacological ResearchSphingosine in apoptosis signaling
2002, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids